Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody (mAb).

Ajinomoto will simplify the supply chain efforts for Humanigen by providing drug product aseptic fill-finish services at its San Diego facility to support continued clinical trial efforts. Humanigen is actively enrolling patients in a phase III study in the U.S. and Brazil and preparing to submit a potential application for emergency use authorization for lenzilumab.

Humanigen expands partnership with BARDA for COVID-19 mAb manufacturing
Humanigen has expanded its cooperative research and development agreement with the U.S. Department of Defense Joint Program Executive Office for Chemical,...

Humanigen, DOD develop COVID-19 mAb
Humanigen is working with the Department of Defense (DOD) to advance its lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor monoclonal...

Ajinomoto introduces new drug manufacturing platform for COVID-19
Ajinomoto Bio-Pharma Services launched Ajility, a flexible drug product manufacturing platform for vaccines and therapies.

Ajinomoto to manufacture COVID-19 drug for Humanigen
Biopharmaceutical contract development and manufacturing firm Ajinomoto has entered into an agreement with Humanigen for the fill-finish supply of lenzilumab....

Trio, Ajinomoto to develop cancer therapeutic
Cancer therapeutics company Trio Pharmaceuticals and biopharmaceutical contract development and manufacturing company Ajinomoto Bio-Pharma Services have...